With Schizophrenia, the peaks and valleys are something no one can control – only the brain.
Schizophrenia is a chronic brain disease that affects less than 1% of the population in the United States. When active, symptoms of schizophrenia include delusions, hallucinations, disorganized speech, difficulty thinking, and a lack of desire. Although there is no cure yet for schizophrenia, the field of research is advancing to innovative safety treatments.
In a study titled Cortical Network Dysfunction as A Marker for Genetic Liability to Schizophrenia, conducted by the Section of Cognitive Psychopharmacology (SCP), schizophrenia was perceived as a widely misunderstood disorder. To further explore the concept, the study seeks to use functional imaging to anticipate how linguistic and memory activities activate brain networks to determine genetic predisposition to schizophrenia. The researchers aim to use functional magnetic resonance imaging to investigate neurocognitive network activation (fMRI).
Dr. Tonmoy Sharma, Principal Investigator of the SCP, found in this study that schizophrenics and “obligate carriers” with a genetic predisposition to schizophrenia will show abnormal network activation patterns when contrasted to unaffected siblings and controls. Thus, the abnormality will be noticeable to a lesser degree in “obligate carriers” than in people with schizophrenia.
The Man Behind Schizophrenia and Sovereign Health
Dr. Tonmoy Sharma, a renowned Indian American psychiatrist with a storied record of studies in the areas of mental health, mainly psychiatric disorders such as schizophrenia, acted as the Principal Investigator in the Section of Cognitive Psychopharmacology (SCP). The SCP is a non-profit research organization founded in 1998 under the Institute of Psychiatry’s Department of Psychological Medicine.
Dr. Sharma’s dedication to the cause of mental health has never faltered since his time at the SCP. Throughout his career, which began at a Medical College in Assam, India and culminated in a Masters in neuroscience at Guildhall College in London, he always prioritized the people in the rear – the patients.
Regardless of how far his reputation and association had reached, Dr. Sharma never ceases to raise significant issues that are vital to medical research and community, as well as policymakers. Through this study, he has tackled the role of heredity, the link between aggressive behavior and schizophrenia, and the impact of the new age – atypical antipsychotics in treatment, in light of the stigma correlated with mental health illnesses, for instance, schizophrenia.
With his continuous dedication to addressing the cognitive unknowns of mental health, he established a valuable reputation as one of the few leading experts in the behavioral healthcare industry in America. By his collaboration with the Joint Commission and the NAMI, Orange County, Dr. Tonmoy Sharma built the reputation of Sovereign Health, being the CEO.
Currently, Dr. Sharma is globally acclaimed as one of the few people who has successfully leveraged his significant experience in mental health and psychiatric diseases to improve treatment outcomes for various conditions, including dual diagnosis.
With Sovereign Health, Dr. Sharma’s dedication to addressing mental well-being resonates the company’s aim to offer a broad spectrum of high-quality behavioral health treatment services for adults and adolescents and family support services. Over the years, Sovereign Health managed to live up to its purpose, touching the lives of thousands of people left in the void of depression and addiction.